Microbleeds and Cerebral Amyloid Angiopathy in the Brains of People with Down Syndrome with Alzheimer's Disease.
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Alzheimer Disease
/ complications
Amyloid beta-Peptides
/ analysis
Autopsy
Case-Control Studies
Cerebral Amyloid Angiopathy
/ pathology
Child
Child, Preschool
Down Syndrome
/ complications
Female
Frontal Lobe
/ pathology
Humans
Image Processing, Computer-Assisted
Intracranial Hemorrhages
/ pathology
Male
Middle Aged
Occipital Lobe
/ pathology
Peptide Fragments
/ analysis
Young Adult
Cerebral amyloid angiopathy
Prussian blue
microhemorrhages
trisomy 21
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
20
11
2018
medline:
3
3
2020
entrez:
20
11
2018
Statut:
ppublish
Résumé
Cerebrovascular pathology is a significant mediator in Alzheimer's disease (AD) in the general population. In people with Down syndrome (DS), the contribution of vascular pathology to dementia may play a similar role in age of onset and/or the rate of progression of AD. In the current study, we explored the extent of microbleeds (MBs) and the link between cerebral amyloid angiopathy (CAA) and MBs in the frontal cortex (FCTX) and occipital cortex (OCTX) in an autopsy series from individuals with DS (<40 years), DS with AD pathology (DSAD), sporadic AD, and control cases (2-83 years). Sections were immunostained against Aβ1 - 40 and an adjacent section stained using Prussian blue for MBs. MBs were both counted and averaged in each case and CAA was scored based on previously published methods. MBs were more frequent in DS cases relative to controls but present to a similar extent as sporadic AD. This aligned with CAA scores, with more extensive CAA in DS relative to controls in both brain regions. CAA was also more frequent in DSAD cases relative to sporadic AD. We found CAA to be associated with MBs and that MBs increased with age in DS after 30 years of age in the OCTX and after 40 years of age in the FCTX. MB and CAA appear to be a significant contributors to the development of dementia in people with DS and are important targets for future clinical trials.
Identifiants
pubmed: 30452414
pii: JAD180589
doi: 10.3233/JAD-180589
pmc: PMC6424116
mid: NIHMS1016412
doi:
Substances chimiques
Amyloid beta-Peptides
0
Peptide Fragments
0
amyloid beta-protein (1-40)
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-112Subventions
Organisme : NIA NIH HHS
ID : P30 AG028383
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG051412
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD064993
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001414
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG021912
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016573
Pays : United States
Références
Curr Alzheimer Res. 2016;13(1):18-29
pubmed: 26651341
Neurol Neurochir Pol. 2015;49(3):193-6
pubmed: 26048609
Stroke. 1987 Mar-Apr;18(2):311-24
pubmed: 3551211
J Intellect Disabil Res. 1997 Feb;41 ( Pt 1):76-80
pubmed: 9089462
Ann Neurol. 1995 Mar;37(3):294-9
pubmed: 7695229
Tohoku J Exp Med. 1994 Nov;174(3):189-98
pubmed: 7761984
Acta Neuropathol. 1998 Feb;95(2):213-6
pubmed: 9498059
Alzheimers Dement. 2015 Jun;11(6):700-9
pubmed: 25510383
Eur J Public Health. 2007 Apr;17(2):221-5
pubmed: 16857692
Acta Neuropathol. 2009 Oct;118(4):505-17
pubmed: 19360426
Ann Neurol. 1985 Mar;17(3):278-82
pubmed: 3158266
J Intellect Disabil Res. 2009 May;53(5):419-25
pubmed: 19228275
J Neuroinflammation. 2004 Dec 08;1(1):24
pubmed: 15588287
Lancet Neurol. 2016 Aug;15(9):934-943
pubmed: 27312738
J Neural Transm (Vienna). 2002 May;109(5-6):813-36
pubmed: 12111471
Br Med J. 1977 Jul 23;2(6081):226-8
pubmed: 141966
Alzheimers Dement. 2017 Nov;13(11):1251-1260
pubmed: 28463681
Biol Psychiatry. 2018 Feb 15;83(4):311-319
pubmed: 28967385
Neurobiol Aging. 2017 Jan;49:86-99
pubmed: 27776266
J Clin Neurol. 2011 Mar;7(1):1-9
pubmed: 21519520
Amyloid. 2008 Dec;15(4):275-7
pubmed: 19065301
J Neurol Neurosurg Psychiatry. 1998 Sep;65(3):405-6
pubmed: 9728967
Nat Rev Neurosci. 2012 Dec;13(12):844-58
pubmed: 23165261
F1000Res. 2016 May 12;5:
pubmed: 27239286
Am J Ment Retard. 2002 May;107(3):161-74
pubmed: 11966329
Free Radic Biol Med. 2018 Jan;114:3-9
pubmed: 28870521
Neurology. 2015 Dec 1;85(22):1930-6
pubmed: 26537052
Clin Genet. 2002 Nov;62(5):390-3
pubmed: 12431254
Neurology. 2013 Nov 26;81(22):1930-7
pubmed: 24174590
Neurobiol Aging. 2014 Jul;35(7):1562-9
pubmed: 24582640
Ann Neurol. 2011 Dec;70(6):871-80
pubmed: 22190361
Acta Neuropathol Commun. 2017 Dec 01;5(1):93
pubmed: 29195510
Exp Gerontol. 2012 Nov;47(11):853-7
pubmed: 22824542
J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):982-994
pubmed: 28844070
Brain. 2006 Nov;129(Pt 11):2966-76
pubmed: 16959815
Ann N Y Acad Sci. 2002 Nov;977:9-23
pubmed: 12480729
Exp Gerontol. 2012 Nov;47(11):838-42
pubmed: 22944481
Dev Disabil Res Rev. 2013;18(1):51-67
pubmed: 23949829
Neurobiol Aging. 2015 Sep;36(9):2468-74
pubmed: 26103884
Brain Pathol. 2017 Jan;27(1):77-85
pubmed: 26844934
Birth Defects Res A Clin Mol Teratol. 2010 Dec;88(12):1008-16
pubmed: 20878909
Nat Genet. 2006 Jan;38(1):24-6
pubmed: 16369530
Folia Neuropathol. 2010;48(3):206-11
pubmed: 20925005
Radiology. 2018 Apr;287(1):11-28
pubmed: 29558307
Br J Clin Psychol. 2008 Mar;47(Pt 1):1-29
pubmed: 17681112
J Neuropathol Exp Neurol. 2013 Jul;72(7):708-15
pubmed: 23771217
J Neurol Sci. 1989 Feb;89(2-3):169-79
pubmed: 2522541